The information provided by is not a substitute for professional medical advice, diagnosis or treatment. The views and opinions expressed on the site do not necessarily represent those of Drugwatch. Sponsored by The Peterson Firm, LLP with offices at 1050 30th Street NW, Washington, . 20007. If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of "Fair Use" and legitimately infringes on yours or your client's copyright, we may be contacted concerning copyright matters at: webmaster@
Median (IQR) patient age in the treatment group was years (-), and initial laboratory results included testosterone ng/dl (-), prostate specific antigen ng/ml (-), hemoglobin gm/dl (-) and hematocrit % (-). Median followup was months, at which time a significant increase in testosterone was observed in the treatment group. A significant increase in prostate specific antigen was observed in the high risk and nonhigh risk treatment groups with no increase in the reference group. Overall 4 and 8 cases of cancer recurrence were observed in treatment and reference groups, respectively.